Indivior Pharmaceuticals (INDV) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Indivior Pharmaceuticals (INDV) over the past year, gaining 226.6% versus a gain of 47.3%. Over five years, INDV leads with a +123.7% price change compared with +60.9% for TNGX. Indivior Pharmaceuticals is the larger company by market cap ($4.23 billion vs $3.89 billion), about 1.1 times the size, while Tango Therapeutics is growing revenue faster (+48.3% vs +4.3%).
Indivior Pharmaceuticals converts more of its revenue into profit, with a net margin of 16.9% versus -162.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INDV | TNGX |
|---|---|---|
| Share price | $35.87 | $23.07 |
| Market cap | $4.23B | $3.89B |
| 1-day change | +1.18% | +2.22% |
| YTD return | -1.20% | +154.74% |
| 1-year return | +47.28% | +226.63% |
| 5-year return | +123.66% | +60.87% |
| P/E ratio (TTM) | 12.86 | — |
| Forward P/E | 7.35 | — |
| EPS (TTM) | $2.79 | $-0.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.24B | $62.38M |
| Revenue growth (YoY) | +4.29% | +48.29% |
| Net income (latest FY) | $210.00M | $-101.59M |
| Gross margin | 80.23% | — |
| Operating margin | 21.15% | -178.39% |
| Net margin | 16.95% | -162.85% |
| 52-week high | $42.81 | $34.39 |
| 52-week low | $22.95 | $6.69 |
| Distance from 52-week high | -16.21% | -32.92% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +36.60% | +95.84% |
| Average volume | 2.07M | 2.65M |
| Shares outstanding | 118.03M | 168.61M |
| Employees | 827 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed INDV by 179.3 percentage points over the past year.
- Indivior Pharmaceuticals is more profitable, keeping 16.9 cents of every revenue dollar as net income versus -162.9 cents for Tango Therapeutics.
- Tango Therapeutics grew revenue faster in its latest fiscal year (+48.29% vs +4.29%).
About Indivior Pharmaceuticals
INDV stock →Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
INDV vs TNGX FAQ
Which is bigger, Indivior Pharmaceuticals or Tango Therapeutics?
Indivior Pharmaceuticals (INDV) is larger, with a market capitalization of $4.23B compared with $3.89B for Tango Therapeutics (TNGX).
Which stock has performed better over the past year, INDV or TNGX?
TNGX returned +226.63% over the past 12 months, compared with +47.28% for INDV (price return, excluding dividends). Past performance does not predict future results.
Are Indivior Pharmaceuticals and Tango Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.